In contrast, PPARγ dominant-negative mutations result in hypertension and insulin resistance, suggesting that a relationship exists between PPARγ function and metabolic syndrome (Plutzky, 2011; Christofides et al., 2021). Here, PPARG is linked to hypertensive disorder.